Individual Radiosensitivity as a Risk Factor for the Radiation-Induced Acute Radiodermatitis.
acute radiation dermatitis
breast cancer radiotherapy
individual radiosensitivity
radiation induced skin toxicity
risk factors
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
23 Dec 2021
23 Dec 2021
Historique:
received:
21
10
2021
revised:
20
12
2021
accepted:
20
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Up to 95% of irradiated patients suffer from ionizing radiation (IR) induced early skin reaction, acute radiation dermatitis (ARD). Some experts think that additional skin hydration can reduce acute skin reactions. Individual radiosensitivity (IRS) determined from lymphocytes may help to predict acute radiation toxicity. The purpose of this study is to evaluate the clinical manifestation of ARD in different skincare groups during whole breast radiotherapy depending on IRS and other risk factors. A total of 108 early-stage breast cancer patients were randomized into best supportive care (BSC) and additional skincare (ASC) groups. IRS was evaluated using a G2 assay modified with caffeine-induced G2 checkpoint arrest. All patients received a 50 Gy dose to the breast planning target volume (PTV). Clinical assessment of ARD symptoms according to the CTCAE grading scale was performed once a week. IRS was successfully determined for 91 out of 108 patients. A total of 10 patients (11%) had normal IRS, 47 patients (52%) were categorized as radiosensitive, and 34 (37%) as highly radiosensitive. There was no significant difference in the manifestation of ARD between patient groups by skincare or IRS. According to logistic regression, patients with bigger breasts were prone to more severe ARD ( The additional skincare did not improve skin condition during RT. A total of 89% of patients had increased radiosensitivity. IRS determined before RT did not show the predictive value for the manifestation of ARD. Logistic regression revealed that breast volume was the most significant risk factor for the manifestation of ARD.
Sections du résumé
BACKGROUND
BACKGROUND
Up to 95% of irradiated patients suffer from ionizing radiation (IR) induced early skin reaction, acute radiation dermatitis (ARD). Some experts think that additional skin hydration can reduce acute skin reactions. Individual radiosensitivity (IRS) determined from lymphocytes may help to predict acute radiation toxicity. The purpose of this study is to evaluate the clinical manifestation of ARD in different skincare groups during whole breast radiotherapy depending on IRS and other risk factors.
METHODS
METHODS
A total of 108 early-stage breast cancer patients were randomized into best supportive care (BSC) and additional skincare (ASC) groups. IRS was evaluated using a G2 assay modified with caffeine-induced G2 checkpoint arrest. All patients received a 50 Gy dose to the breast planning target volume (PTV). Clinical assessment of ARD symptoms according to the CTCAE grading scale was performed once a week.
RESULTS
RESULTS
IRS was successfully determined for 91 out of 108 patients. A total of 10 patients (11%) had normal IRS, 47 patients (52%) were categorized as radiosensitive, and 34 (37%) as highly radiosensitive. There was no significant difference in the manifestation of ARD between patient groups by skincare or IRS. According to logistic regression, patients with bigger breasts were prone to more severe ARD (
CONCLUSIONS
CONCLUSIONS
The additional skincare did not improve skin condition during RT. A total of 89% of patients had increased radiosensitivity. IRS determined before RT did not show the predictive value for the manifestation of ARD. Logistic regression revealed that breast volume was the most significant risk factor for the manifestation of ARD.
Identifiants
pubmed: 35054413
pii: life12010020
doi: 10.3390/life12010020
pmc: PMC8781761
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : International Atomic Energy Agency
ID : CRP E35010
Références
J Am Acad Dermatol. 2019 Aug;81(2):558-567
pubmed: 30802561
Curr Oncol. 2019 Dec;26(6):380-388
pubmed: 31896936
Radiother Oncol. 2011 Oct;101(1):28-34
pubmed: 22014898
Front Oncol. 2019 Oct 01;9:987
pubmed: 31632918
Clin Oncol (R Coll Radiol). 1996;8(4):226-33
pubmed: 8871000
Radiography (Lond). 2020 Aug;26(3):192-197
pubmed: 32052757
Hered Cancer Clin Pract. 2013 Sep 11;11(1):12
pubmed: 24025454
Jpn J Radiol. 2012 Jul;30(6):486-91
pubmed: 22528337
Radiat Res. 1994 Apr;138(1 Suppl):S40-3
pubmed: 8146323
Exp Oncol. 2012 Jul;34(2):121-4
pubmed: 23013765
Curr Oncol. 2010 Aug;17(4):94-112
pubmed: 20697521
Radiother Oncol. 2000 May;55(2):179-86
pubmed: 10799730
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):379-89
pubmed: 11173131
Support Care Cancer. 2013 Apr;21(4):1025-31
pubmed: 23064885
J Invest Dermatol. 2012 Mar;132(3 Pt 2):985-93
pubmed: 22217743
Surg Oncol. 2015 Sep;24(3):200-11
pubmed: 26116397
Cancers (Basel). 2021 May 19;13(10):
pubmed: 34069662
Curr Oncol. 2018 Apr;25(2):e176-e180
pubmed: 29719442
Oncol Rep. 2005 Feb;13(2):347-53
pubmed: 15643523
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Genome Integr. 2010 Jun 24;1(1):9
pubmed: 20678261
Support Care Cancer. 2006 Aug;14(8):802-17
pubmed: 16758176
J Contemp Brachytherapy. 2012 Dec;4(4):219-26
pubmed: 23378851
Ann Surg Oncol. 2018 Jan;25(1):137-147
pubmed: 29110277
Semin Oncol Nurs. 2011 May;27(2):e1-17
pubmed: 21514477
J Natl Compr Canc Netw. 2017 Apr;15(4):433-451
pubmed: 28404755
Dose Response. 2020 May 8;18(2):1559325820913784
pubmed: 32425719
Radiat Oncol. 2012 Dec 18;7:217
pubmed: 23249653
Radiol Oncol. 2014 Jan 22;48(1):80-6
pubmed: 24587784
Breast Cancer Res Treat. 2017 Apr;162(3):409-417
pubmed: 28160158
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):256-64
pubmed: 18406889
J Radiat Res. 2010;51(5):615-9
pubmed: 20921829
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865
Radiat Oncol. 2011 Apr 07;6:32
pubmed: 21473753
Int J Radiat Biol. 2005 May;81(5):373-8
pubmed: 16076752